Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 6/2012

01-12-2012 | Nephrology - Case Report

Minimal change disease associated with MALT lymphoma

Authors: Rahil Kasmani, Vamsee Priya Marina, Syed Abidi, Bikram Johar, Deepak Malhotra

Published in: International Urology and Nephrology | Issue 6/2012

Login to get access

Abstract

Low-grade Extranodal Marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, a subtype of non-Hodgkin’s Lymphoma, involving the kidney is a rare clinical entity. Association of Minimal change disease nephrotic range proteinuria with Hodgkin’s lymphoma is well described, however is extremely uncommon with non-Hodgkin’s lymphoma. We describe a patient who presented with nephrotic syndrome and a kidney biopsy revealed marginal zone lymphoma and diffuse epithelial foot process effacement. He showed dramatic response to a combination therapy with cyclophosphamide, corticosteroids, and Rituximab.
Literature
1.
Audard V, Larousserie F, Grimbert P et al (2006) Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int 69(12):2251–2260PubMedCrossRef
2.
Baizhou L, Zhang W, Tian X, Qiu L (2008) Primary renal mucosa-associated lymphoid tissue lymphoma, the result of chronic pyelonephritis? Chin–Ger J Clin Oncol 7(1):55–58CrossRef
3.
Tao J, Kahn L (2000) Epstein-Barr virus-associated high-grade B-cell lymphoma of mucosal-associated lymphoid tissue in a 9-year-old boy. Arch Pathol Lab Med 124(10):1520–1524PubMed
4.
Colović M, Hadzi-Djokić J, Cemerikić V, Colović R, Janković G, Dacić M (1999) Primary MALT lymphoma of the kidney. Hematol Cell Ther 41(5):229–232PubMedCrossRef
5.
Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM (1991) Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol 96(6):738–745PubMed
6.
Mak SK, Wong PN, Lo KY, Wong AK (1998) Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type. Am J Kidney Dis 31(4):713–718PubMedCrossRef
7.
Stokes MB, Wood B, Alpers C (2002) Membranoproliferative glomerulonephritis associated with low-grade B cell lymphoma presenting in the kidney. Clin Nephrol 57(4):303–309PubMed
8.
Garcia M, Konoplev S, Morosan C, Abruzzo LV, Bueso-Ramos CE, Medeiros LJ (2007) MALT lymphoma involving the kidney: a report of 10 cases and review of the literature. Am J Clin Pathol 128(3):464–473PubMedCrossRef
9.
10.
Ronco PM (1999) Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 56(1):355–377PubMedCrossRef
11.
Dabbs DJ, Striker LM, Mignon F, Striker G (1986) Glomerular lesions in lymphomas and leukemias. Am J Med 80(1):63–70PubMedCrossRef
12.
Ghosh L, Muehrcke RC (1970) Nephrotic syndrome: a prodrome to lymphoma. Ann Intern Med 72(3):379–382PubMed
13.
Gagliano RG, Costanzi JJ, Beathard GA, Sarles HE, Bell JD (1976) The nephrotic syndrome associated with neoplasia: an unusual paraneoplastic syndrome. Report of a case and review of the literature. Am J Med 60(7):1026–1031PubMedCrossRef
14.
Aggarwal N, Batwara R, McCarthy ET, Sharma R, Sharma M, Savin VJ (2007) Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis 50(5):826–829PubMedCrossRef
15.
Gilbert RD, Hulse E, Rigden S (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21(11):1698–1700PubMedCrossRef
16.
Yang T, Nast CC, Vo A, Jordan SC (2008) Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 23(1):377–380PubMedCrossRef
17.
Deschênes G, Doucet A (2009) Free immunoglobulin light chains: a role in minimal change disease. Biosci Hypothesis 2(3):135–142CrossRef
Metadata
Title
Minimal change disease associated with MALT lymphoma
Authors
Rahil Kasmani
Vamsee Priya Marina
Syed Abidi
Bikram Johar
Deepak Malhotra
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-011-9992-z

Other articles of this Issue 6/2012

International Urology and Nephrology 6/2012 Go to the issue

Nephrology – Original Paper

Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients

Urology Original Paper

The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis

Urology - Original Paper

Determinants of outcomes after resection of renal cell carcinoma with venous involvement

Nephrology - Original Paper

Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?

Urology - Original Paper

CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy

Nephrology - Original Paper

Presence of glucose in dialyzing fluid and synthesis of selected lipoxygenase-derived eicosanoids during hemodialysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits